Fortress Biotech, Inc. (FBIO)
1.965
+0.20
(+11.02%)
USD |
NASDAQ |
Nov 20, 10:10
Fortress Biotech Cash from Operations (Quarterly) : -6.197M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -6.197M |
| June 30, 2026 | -59.28M |
| March 31, 2026 | 203.85M |
| December 31, 2025 | -18.10M |
| September 30, 2025 | -6.11M |
| June 30, 2025 | -27.56M |
| March 31, 2025 | -19.56M |
| December 31, 2024 | 38.09M |
| September 30, 2024 | -71.06M |
| June 30, 2024 | -21.84M |
| March 31, 2024 | -25.39M |
| December 31, 2023 | -34.94M |
| September 30, 2023 | -16.78M |
| June 30, 2023 | -33.29M |
| March 31, 2023 | -43.22M |
| December 31, 2022 | -47.84M |
| September 30, 2022 | -43.39M |
| June 30, 2022 | -41.42M |
| March 31, 2022 | -46.86M |
| December 31, 2021 | -36.60M |
| September 30, 2021 | -22.20M |
| June 30, 2021 | -36.05M |
| March 31, 2021 | -21.69M |
| December 31, 2020 | -20.49M |
| September 30, 2020 | -23.89M |
| Date | Value |
|---|---|
| June 30, 2020 | -17.41M |
| March 31, 2020 | -21.89M |
| December 31, 2019 | -25.05M |
| September 30, 2019 | -16.26M |
| June 30, 2019 | -28.32M |
| March 31, 2019 | -25.32M |
| December 31, 2018 | |
| September 30, 2018 | -24.76M |
| June 30, 2018 | -24.08M |
| March 31, 2018 | -27.84M |
| December 31, 2017 | -24.59M |
| September 30, 2017 | -26.90M |
| June 30, 2017 | -21.69M |
| March 31, 2017 | -12.63M |
| December 31, 2016 | -17.79M |
| September 30, 2016 | -8.823M |
| June 30, 2016 | -7.382M |
| March 31, 2016 | -11.64M |
| December 31, 2015 | 2.861M |
| September 30, 2015 | -6.537M |
| June 30, 2015 | -7.868M |
| March 31, 2015 | -8.834M |
| December 31, 2014 | -3.527M |
| September 30, 2014 | -2.321M |
| June 30, 2014 | -4.014M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -192.40M |
| Nektar Therapeutics | -71.93M |
| DiaMedica Therapeutics, Inc. | -8.641M |
| Journey Medical Corp. | -3.437M |
| ACADIA Pharmaceuticals, Inc. | 11.50M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.007M |
| Cash from Financing (Quarterly) | -38.19M |
| Free Cash Flow | 120.19M |
| Free Cash Flow Per Share (Quarterly) | -0.1838 |
| Free Cash Flow to Equity (Quarterly) | 8.161M |
| Free Cash Flow to Firm (Quarterly) | -3.723M |
| Free Cash Flow Yield | 182.6% |